Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer

• Prif Awduron: Benjamin K. Schneider (Awdur), Arnaud Boyer (Awdur), Joseph Ciccolini (Awdur), Fabrice Barlesi (Awdur), Kenneth Wang (Awdur), Sebastien Benzekry (Awdur), Jonathan P. Mochel (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Wiley, 2019-08-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Bevacizumab‐pemetrexed/cisplatin (BEV‐PEM/CIS) is a first‐line therapeutic for advanced nonsquamous non‐small cell lung cancer. Bevacizumab potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. BEV‐PEM/CIS has a narrow therapeutic window. Therefore, it is an attract...